Relay Therapeutics, Inc. (RLAY)
Company Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
In addition, it has collaboration and license agreements with D. E.
Shaw Research, LLC to research certain biological targets through the use of D. E.
Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971.
The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015.
Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Country | United States |
Founded | 2015 |
IPO Date | Jul 16, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 323 |
CEO | Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS |
Contact Details
Address: 399 Binney Street, 2nd Floor Cambridge, Massachusetts 02139 United States | |
Phone | 617-370-8837 |
Website | relaytx.com |
Stock Details
Ticker Symbol | RLAY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $20.00 |
CIK Code | 0001812364 |
CUSIP Number | 75943R102 |
ISIN Number | US75943R1023 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Alexis A. Borisy A.M. | Co-Founder and Independent Chairman |
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | Chief Executive Officer, President and Director |
Dr. Mark Murcko Ph.D. | Co-Founder and Director |
Thomas Catinazzo | Chief Financial Officer |
Brian R. Adams J.D. | Chief Legal Officer and Secretary |
Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research and Development |
Peter Rahmer | Chief Corporate Development Officer |
Dr. Deborah Palestrant M.B.A., Ph.D. | Vice President of Corporate Development and Strategy |
Jim Watters Ph.D. | Chief Scientific Officer of Late Research |
Dr. Beni B. Wolf M.D., Ph.D. | Chief Medical Officer and Head of Precision Medicine |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 22, 2024 | 10-K | Annual Report |
Feb 22, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 26, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 10, 2024 | 424B7 | Filing |
Jan 10, 2024 | D | Notice of Exempt Offering of Securities |